- Home
- BHE vs AUPH Comparison
BHE vs AUPH Comparison
Compare BHE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- AUPH
- Stock Information
- Founded
- BHE 1979
- AUPH 1993
- Country
- BHE United States
- AUPH Canada
- Employees
- BHE N/A
- AUPH N/A
- Industry
- BHE Electrical Products
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- BHE Technology
- AUPH Health Care
- Exchange
- BHE Nasdaq
- AUPH Nasdaq
- Market Cap
- BHE 1.3B
- AUPH 1.1B
- IPO Year
- BHE 1990
- AUPH 1999
- Fundamental
- Price
- BHE $37.83
- AUPH $8.19
- Analyst Decision
- BHE Strong Buy
- AUPH Strong Buy
- Analyst Count
- BHE 2
- AUPH 2
- Target Price
- BHE $47.00
- AUPH $11.50
- AVG Volume (30 Days)
- BHE 212.9K
- AUPH 1.4M
- Earning Date
- BHE 07-29-2025
- AUPH 07-31-2025
- Dividend Yield
- BHE 1.80%
- AUPH N/A
- EPS Growth
- BHE N/A
- AUPH N/A
- EPS
- BHE 1.44
- AUPH 0.27
- Revenue
- BHE $2,612,294,000.00
- AUPH $247,295,000.00
- Revenue This Year
- BHE $0.52
- AUPH $12.15
- Revenue Next Year
- BHE $8.50
- AUPH $18.31
- P/E Ratio
- BHE $26.25
- AUPH $30.78
- Revenue Growth
- BHE N/A
- AUPH 29.20
- 52 Week Low
- BHE $30.73
- AUPH $5.15
- 52 Week High
- BHE $52.57
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- BHE 58.10
- AUPH 54.75
- Support Level
- BHE $36.90
- AUPH $7.91
- Resistance Level
- BHE $37.07
- AUPH $8.07
- Average True Range (ATR)
- BHE 0.79
- AUPH 0.24
- MACD
- BHE 0.14
- AUPH -0.00
- Stochastic Oscillator
- BHE 91.26
- AUPH 51.85
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.